GAITHERSBURG, Md., Jan. 3, 2024
/PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company
advancing protein-based vaccines with its Matrix-M™ adjuvant, today
announced that it will participate in the 42th Annual
J.P. Morgan Healthcare Conference.
Conference
Details:
|
|
|
Presentation and
Q&A
|
|
Date:
|
Monday, January 8,
2024
|
Time:
|
5:15 – 5:55 p.m.
Pacific Standard Time (PST)
|
Location:
|
Westin St. Francis
Hotel in San Francisco, California
|
Moderator:
|
Eric Joseph, Ph.D.,
Executive Director, Biotechnology Equity Research
|
Novavax
participants:
|
John C. Jacobs,
President and Chief Executive Officer
|
|
|
|
Conference
|
|
Event:
|
Investor
Meetings
|
Date:
|
Monday, January 8,
2024
|
Recordings
A replay of the recorded presentation and
Q&A will be available through the Events & presentations
page of the Company's website at ir.novavax.com for 30 days
from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes
improved health by discovering, developing and commercializing
innovative vaccines to help protect against serious infectious
diseases. Novavax, a global company based in Gaithersburg,
Md., U.S., offers a differentiated vaccine platform that combines a
recombinant protein approach, innovative nanoparticle technology
and Novavax's patented Matrix-M adjuvant to enhance the immune
response. Focused on the world's most urgent health challenges,
Novavax is currently evaluating vaccines for COVID-19, influenza
and COVID-19 and influenza combined. Please
visit novavax.com and LinkedIn for more
information.
Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com
Media
Ali Chartan
240-720-7804
media@novavax.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-the-42nd-annual-jp-morgan-healthcare-conference-302024821.html
SOURCE NOVAVAX, INC